Abstract
We present a case of a 64-year-old woman with neurofibromatosis (NF1) and smoldering multiple myeloma (SMM). SMM was diagnosed 9 years ago when the asymptomatic patient was found to have mild anemia, IgA paraproteinemia, hypogammaglobulinemia, osteopenia without any lytic bone lesions and bone marrow plasmacytosis. During follow-up period she remained stable in an excellent clinical condition without requiring any therapy for almost 4 years. Forty-two months after diagnosis she had a femoral fracture and since then biphosphonates have been administered intravenously, once monthly. Subsequent evaluations of the disease showed a dramatic reduction of IgA paraprotein to below half the initial value. We will discuss the probable pathogenesis of plasma cell dyscrasia in NF1 patients, as well as the likely antimyeloma activity of biphoshonates.
References
Mar 3, 1994·The New England Journal of Medicine·K M ShannonF McCormick
Mar 31, 1998·Leukemia·P BriceC Gisselbrecht
Mar 31, 1998·Leukemia·A AparicioA Lichtenstein
Jul 31, 1998·Leukemia & Lymphoma·P Musto
Oct 31, 1998·Oncogene·R ManguesA Pellicer
Jan 28, 1999·Leukemia & Lymphoma·P Musto
Dec 8, 2000·The Oncologist·B R Korf
Apr 20, 2001·Seminars in Hematology·J R Berenson
Dec 12, 2001·British Journal of Haematology·UNKNOWN UK myeloma forum. British Committee for Standards in Haematology
Aug 3, 2002·Leukemia & Lymphoma·Haruki Kondo, Akinori Mori
Dec 4, 2002·European Journal of Haematology·Esa Jantunen
Mar 6, 2003·Reviews in Clinical and Experimental Hematology·Jean-Luc Harousseau
Apr 12, 2003·Leukemia & Lymphoma·Haruki KondoMichio Kubota
May 10, 2003·Lancet·R M ReynoldsI W Campbell
Sep 11, 2003·The Lancet Oncology·Sonja SeidlJohannes Drach
Nov 18, 2003·British Journal of Haematology·L RosiñolE Montserrat
Jul 13, 2004·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Daniele SantiniGiuseppe Tonini